Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue: +10.4%
EPS: −280.5%
Free cash flow: −60.4%
Total debt: +3.88%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

235.25 7.93 +3.49%

Follow JAZZ

Alert me

Market cap: $14.6B
P/E: 64.7×
Fwd P/E: 35.9×
Dividend yield: —
F-score: 5/9
Altman Z: 1.37
Beneish M: −3.03
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Jazz Pharmaceuticals PLC 10-K filed Feb 24, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed Feb 24, 2026 · accepted 4:10 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 26, 2025: 43 added · 46 removed · 79 modified; 11 with only figures updated; 3 moved without change

Jazz Pharmaceuticals PLC 10-K filed Feb 24, 2026

What changed

Stockrow Weekly